<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34914868</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1533-4406</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>386</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>The New England journal of medicine</Title>
          <ISOAbbreviation>N Engl J Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.</ArticleTitle>
        <Pagination>
          <StartPage>509</StartPage>
          <EndPage>520</EndPage>
          <MedlinePgn>509-520</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">NEJMoa2116044</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2116044</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</AbstractText>
          <AbstractText Label="METHODS">We conducted a phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of treatment with molnupiravir started within 5 days after the onset of signs or symptoms in nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed Covid-19 and at least one risk factor for severe Covid-19 illness. Participants in the trial were randomly assigned to receive 800 mg of molnupiravir or placebo twice daily for 5 days. The primary efficacy end point was the incidence hospitalization or death at day 29; the incidence of adverse events was the primary safety end point. A planned interim analysis was performed when 50% of 1550 participants (target enrollment) had been followed through day 29.</AbstractText>
          <AbstractText Label="RESULTS">A total of 1433 participants underwent randomization; 716 were assigned to receive molnupiravir and 717 to receive placebo. With the exception of an imbalance in sex, baseline characteristics were similar in the two groups. The superiority of molnupiravir was demonstrated at the interim analysis; the risk of hospitalization for any cause or death through day 29 was lower with molnupiravir (28 of 385 participants [7.3%]) than with placebo (53 of 377 [14.1%]) (difference, -6.8 percentage points; 95% confidence interval [CI], -11.3 to -2.4; P = 0.001). In the analysis of all participants who had undergone randomization, the percentage of participants who were hospitalized or died through day 29 was lower in the molnupiravir group than in the placebo group (6.8% [48 of 709] vs. 9.7% [68 of 699]; difference, -3.0 percentage points; 95% CI, -5.9 to -0.1). Results of subgroup analyses were largely consistent with these overall results; in some subgroups, such as patients with evidence of previous SARS-CoV-2 infection, those with low baseline viral load, and those with diabetes, the point estimate for the difference favored placebo. One death was reported in the molnupiravir group and 9 were reported in the placebo group through day 29. Adverse events were reported in 216 of 710 participants (30.4%) in the molnupiravir group and 231 of 701 (33.0%) in the placebo group.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19. (Funded by Merck Sharp and Dohme; MOVe-OUT ClinicalTrials.gov number, NCT04575597.).</AbstractText>
          <CopyrightInformation>Copyright © 2021 Massachusetts Medical Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jayk Bernal</LastName>
            <ForeName>Angélica</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomes da Silva</LastName>
            <ForeName>Monica M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Musungaie</LastName>
            <ForeName>Dany B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kovalchuk</LastName>
            <ForeName>Evgeniy</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonzalez</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Delos Reyes</LastName>
            <ForeName>Virginia</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martín-Quirós</LastName>
            <ForeName>Alejandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Caraco</LastName>
            <ForeName>Yoseph</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Williams-Diaz</LastName>
            <ForeName>Angela</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Michelle L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Jiejun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pedley</LastName>
            <ForeName>Alison</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Assaid</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strizki</LastName>
            <ForeName>Julie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grobler</LastName>
            <ForeName>Jay A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shamsuddin</LastName>
            <ForeName>Hala H</ForeName>
            <Initials>HH</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tipping</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paschke</LastName>
            <ForeName>Amanda</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Butterton</LastName>
            <ForeName>Joan R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Matthew G</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Anda</LastName>
            <ForeName>Carisa</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>MOVe-OUT Study Group</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT04575597</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>N Engl J Med</MedlineTA>
        <NlmUniqueID>0255562</NlmUniqueID>
        <ISSNLinking>0028-4793</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2022 Feb 10;386(6):592-593</RefSource>
          <PMID Version="1">34914869</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Pol Arch Intern Med. 2022 Jan 28;132(1):</RefSource>
          <PMID Version="1">34978394</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2022 Mar 31;386(13):e32</RefSource>
          <PMID Version="1">35294804</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2022 Mar 31;386(13):e32</RefSource>
          <PMID Version="1">35294805</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2022 Mar 31;386(13):e32</RefSource>
          <PMID Version="1">35294806</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2022 Mar 31;386(13):e32</RefSource>
          <PMID Version="1">35294807</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Ann Intern Med. 2022 Apr;175(4):JC40</RefSource>
          <PMID Version="1">35377719</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <InvestigatorList>
        <Investigator ValidYN="Y">
          <LastName>Doreski</LastName>
          <ForeName>Pablo</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lobo</LastName>
          <ForeName>Suzana Margareth Ajeje</ForeName>
          <Initials>SMA</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kallás</LastName>
          <ForeName>Ésper</ForeName>
          <Initials>É</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gomes da Silva</LastName>
          <ForeName>Monica Maria</ForeName>
          <Initials>MM</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Souto Lopes</LastName>
          <ForeName>Suzara</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Golin</LastName>
          <ForeName>Nicole Alberti</ForeName>
          <Initials>NA</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tytus</LastName>
          <ForeName>Richard</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cruz</LastName>
          <ForeName>Germán</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Rodríguez</LastName>
          <ForeName>Ignacio</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Fernández</LastName>
          <ForeName>Plinio</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Elgueta</LastName>
          <ForeName>Sergio</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Perez</LastName>
          <ForeName>Carlos</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Moncada</LastName>
          <ForeName>Pablo Andres</ForeName>
          <Initials>PA</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Figueredo</LastName>
          <ForeName>Mario</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Iglesias</LastName>
          <ForeName>Shirley Patricia</ForeName>
          <Initials>SP</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Jayk Bernal</LastName>
          <ForeName>Angelica María</ForeName>
          <Initials>AM</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Roa Buitrago</LastName>
          <ForeName>Jairo</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bautista</LastName>
          <ForeName>Leonardo</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Fernandez</LastName>
          <ForeName>Angela</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Accini</LastName>
          <ForeName>Jose</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Abdel Aziz</LastName>
          <ForeName>Ehab</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Robineau</LastName>
          <ForeName>Olivier</ForeName>
          <Initials>O</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ghosn</LastName>
          <ForeName>Jade</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Katlama</LastName>
          <ForeName>Christine</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wolf</LastName>
          <ForeName>Timo</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Flores</LastName>
          <ForeName>Jose</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lopez</LastName>
          <ForeName>Rudy</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bassetti</LastName>
          <ForeName>Matteo</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ohmagari</LastName>
          <ForeName>Norio</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Umezawa</LastName>
          <ForeName>Yoshihiro</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Takiguchi</LastName>
          <ForeName>Yasuo</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Garcia Salcido</LastName>
          <ForeName>Roxana</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ponce de León Garduño</LastName>
          <ForeName>Luis Alfredo</ForeName>
          <Initials>LA</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Camacho-Ortiz</LastName>
          <ForeName>Adrian</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mosqueda Gomez</LastName>
          <ForeName>Juan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ramirez Hernandez</LastName>
          <ForeName>Amado</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Campos</LastName>
          <ForeName>Jesus Simon</ForeName>
          <Initials>JS</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Rivera Martinez</LastName>
          <ForeName>Norma</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Medina</LastName>
          <ForeName>Isai</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Castro Castrezana</LastName>
          <ForeName>Laura</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Muniz</LastName>
          <ForeName>Alejandro</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Delos Reyes</LastName>
          <ForeName>Virginia</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Santiaguel</LastName>
          <ForeName>Joel</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Khaertynova</LastName>
          <ForeName>Ilsiyar</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ploskireva</LastName>
          <ForeName>Antonina</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lomakin</LastName>
          <ForeName>Nikita</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kozlov</LastName>
          <ForeName>Roman S</ForeName>
          <Initials>RS</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Galustyan</LastName>
          <ForeName>Anna Nikolaevna</ForeName>
          <Initials>AN</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kovalchuk</LastName>
          <ForeName>Evgeniy</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Zakharov</LastName>
          <ForeName>Konstantin</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kostenko</LastName>
          <ForeName>Victor Avenirovich</ForeName>
          <Initials>VA</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tomaev</LastName>
          <ForeName>Uruzmag</ForeName>
          <Initials>U</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pichkov</LastName>
          <ForeName>Dmitriy</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Antonova</LastName>
          <ForeName>Elizaveta</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chizhova</LastName>
          <ForeName>Olga</ForeName>
          <Initials>O</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Arkharov</LastName>
          <ForeName>Igor</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Anikin</LastName>
          <ForeName>Georgiy</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lioznov</LastName>
          <ForeName>Dmitry</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Burgess</LastName>
          <ForeName>Lesley</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Fourie</LastName>
          <ForeName>Nyda</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Badat</LastName>
          <ForeName>Aysha</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Van Zyl</LastName>
          <ForeName>Louis</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hellstrom</LastName>
          <ForeName>Elizabeth</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kassim</LastName>
          <ForeName>Sheetal</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Musungaie</LastName>
          <ForeName>Dany Badibanga</ForeName>
          <Initials>DB</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Petrick</LastName>
          <ForeName>Friedrich Georg</ForeName>
          <Initials>FG</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Fouche</LastName>
          <ForeName>Leon</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Coetzee</LastName>
          <ForeName>Kathleen</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mngqibisa</LastName>
          <ForeName>Rosie</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mellet</LastName>
          <ForeName>Karla</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Quíros</LastName>
          <ForeName>Alejandro Martín</ForeName>
          <Initials>AM</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mateu</LastName>
          <ForeName>Lourdes</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Brotons Cuixart</LastName>
          <ForeName>Carlos</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>de Carranza Lopez</LastName>
          <ForeName>Maria</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cheng</LastName>
          <ForeName>Chien-Yu</ForeName>
          <Initials>CY</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chang</LastName>
          <ForeName>Shan-Chwen</ForeName>
          <Initials>SC</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bhagani</LastName>
          <ForeName>Sanjay</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Samoilova</LastName>
          <ForeName>Svitlana</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ostrovskyy</LastName>
          <ForeName>Mykola</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kobrynska</LastName>
          <ForeName>Olena</ForeName>
          <Initials>O</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pryshliak</LastName>
          <ForeName>Oleksandra</ForeName>
          <Initials>O</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Logoida</LastName>
          <ForeName>Pavlo</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gyrina</LastName>
          <ForeName>Olga</ForeName>
          <Initials>O</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kireyev</LastName>
          <ForeName>Igor</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Koval</LastName>
          <ForeName>Tetiana</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Berenfus</LastName>
          <ForeName>Vadym</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Peresh</LastName>
          <ForeName>Liudmyla</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Levchenko</LastName>
          <ForeName>Olena</ForeName>
          <Initials>O</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Crofoot</LastName>
          <ForeName>Gordon E</ForeName>
          <Initials>GE</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gonzalez</LastName>
          <ForeName>Antonio</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Surber</LastName>
          <ForeName>Joseph</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Duke</LastName>
          <ForeName>Elizabeth</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sims</LastName>
          <ForeName>James</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ramgopal</LastName>
          <ForeName>Moti</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kemp</LastName>
          <ForeName>Charles</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Zambrano</LastName>
          <ForeName>Carlos</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cohen</LastName>
          <ForeName>Jonathan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Katzman</LastName>
          <ForeName>Steven</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Weinberg</LastName>
          <ForeName>Aaron</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cardona</LastName>
          <ForeName>Jose</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Delgado</LastName>
          <ForeName>Lisette</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ginsberg</LastName>
          <ForeName>Daniel</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mills</LastName>
          <ForeName>Anthony</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pelayo</LastName>
          <ForeName>Enrique</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Grayson Mathis</LastName>
          <ForeName>Charlotte</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Call</LastName>
          <ForeName>Robert</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Graham</LastName>
          <ForeName>Mary Beth</ForeName>
          <Initials>MB</Initials>
        </Investigator>
      </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>17</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34914868</ArticleId>
        <ArticleId IdType="pmc">PMC8693688</ArticleId>
        <ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>WHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization, 2021.  (https://covid19.who.int).</Citation>
        </Reference>
        <Reference>
          <Citation>Stokes EK, Zambrano LD, Anderson KN, et al.
Coronavirus disease 2019 case surveillance — United States, January 22–May 30, 2020.
MMWR Morb Mortal Wkly Rep
2020;69:759-765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7302472</ArticleId>
            <ArticleId IdType="pubmed">32555134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko JY, Danielson ML, Town M, et al.
Risk factors for coronavirus disease 2019 (COVID-19)–associated hospitalization: COVID-19–associated hospitalization surveillance network and behavioral risk factor surveillance system.
Clin Infect Dis
2021;72(11):e695-e703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7543371</ArticleId>
            <ArticleId IdType="pubmed">32945846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kompaniyets L, Goodman AB, Belay B, et al.
Body mass index and risk for COVID-19-related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death — United States, March–December 2020.
MMWR Morb Mortal Wkly Rep
2021;70:355-361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7951819</ArticleId>
            <ArticleId IdType="pubmed">33705371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagner CE, Saad-Roy CM, Morris SE, et al.
Vaccine nationalism and the dynamics and control of SARS-CoV-2.
Science
2021;373(6562):eabj7364-eabj7364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34404735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen KH, Nguyen K, Corlin L, Allen JD, Chung M. Changes in COVID-19 vaccination receipt and intention to vaccinate by socioeconomic characteristics and geographic area, United States, January 6 — March 29, 2021.
Ann Med
2021;53:1419-1428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8425688</ArticleId>
            <ArticleId IdType="pubmed">34482788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arribas JR, Bhagani S, Lobo S, et al.
Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19.
NEJM Evid. DOI: 10.1056/EVIDoa2100044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/EVIDoa2100044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID-19.
Viruses
2021;13:628-628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8067572</ArticleId>
            <ArticleId IdType="pubmed">33916927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, Gonzalez-Rojas Y, Juarez E, et al.
Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab.
N Engl J Med
2021;385:1941-1950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34706189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer W, Eron JJ Jr., Holman W, et al.
Molnupiravir, an oral antiviral treatment for COVID-19.
June
17, 2021.  (https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1). preprint.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen MS, Wohl DA, Fischer WA, Smith DM, Eron JJ. Outpatient treatment of SARS-CoV-2 infection to prevent COVID-19 progression.
Clin Infect Dis
2021;73:1717-1721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8194682</ArticleId>
            <ArticleId IdType="pubmed">34048568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon JJ, Toots M, Lee S, et al.
Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses.
Antimicrob Agents Chemother
2018;62(8):e00766-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6105843</ArticleId>
            <ArticleId IdType="pubmed">29891600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
Nat Microbiol
2021;6:11-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan TP, Sims AC, Zhou S, et al.
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Sci Transl Med
2020;12(541):eabb5883-eabb5883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A, Gralinski LE, Johnson CE, et al.
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
Nature
2021;591:451-457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J. Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model.
J Infect Dis
2021;224:749-753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8408768</ArticleId>
            <ArticleId IdType="pubmed">34244768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini ML, Pruijssers AJ, Chappell JD, et al.
Small-molecule antiviral beta-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance.
J Virol
2019;93(24):e01348-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urakova N, Kuznetsova V, Crossman DK, et al.
β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome.
J Virol
2018;92(3):e01965-e17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5774879</ArticleId>
            <ArticleId IdType="pubmed">29167335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grobler J, Strizki J, Murgolo N, et al.
Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies. In: Proceedings and abstracts of IDWeek 2021, September 29–October 3, 2021. Arlington, VA: Infectious Diseases Society of America, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Kabinger F, Stiller C, Schmitzová J, et al.
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
Nat Struct Mol Biol
2021;28:740-746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8437801</ArticleId>
            <ArticleId IdType="pubmed">34381216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
J Biol Chem
2021;297:100770-100770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8110631</ArticleId>
            <ArticleId IdType="pubmed">33989635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malone B, Campbell EA. Molnupiravir: coding for catastrophe.
Nat Struct Mol Biol
2021;28:706-708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34518697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter WP, Holman W, Bush JA, et al.
Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2.
Antimicrob Agents Chemother
2021;65(5):e02428-20-e02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoo SH, Fitzgerald R, Fletcher T, et al.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother
2021;76:3286-3295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8598307</ArticleId>
            <ArticleId IdType="pubmed">34450619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chawla A, Cao Y, Stone J, et al.
Model-based dose selection for the phase 3 evaluation of molnupiravir (MOV) in the treatment of COVID-19 in adults. In: Proceedings and abstracts of the 31st Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases, July 9–12, 2021. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>COVID-19: developing drugs and biological products for treatment or prevention: guidance for industry. Silver Spring, MD: Food and Drug Administration, May
2020.  (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention).</Citation>
        </Reference>
        <Reference>
          <Citation>WHO COVID-19 case definitions. Geneva: World Health Organization, December
16, 2020.  (https://apps.who.int/iris/rest/bitstreams/1322790/retrieve).</Citation>
        </Reference>
        <Reference>
          <Citation>Miettinen O, Nurminen M. Comparative analysis of two rates.
Stat Med
1985;4:213-226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4023479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error probability spending functions.
Stat Med
1990;9:1439-1445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2281231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg ES, Holtgrave DR, Dorabawila V, et al.
New COVID-19 cases and hospitalizations among adults, by vaccination status — New York, May 3–July 25, 2021.
MMWR Morb Mortal Wkly Rep
2021;70:1306-1311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8445378</ArticleId>
            <ArticleId IdType="pubmed">34529645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caraco Y, Crofoot G, Moncada PA, et al.
Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults.
NEJM Evid. DOI: 10.1056/EVIDoa2100043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/EVIDoa2100043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tenforde MW, Kim SS, Lindsell CJ, et al.
Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March–June 2020.
MMWR Morb Mortal Wkly Rep
2020;69:993-998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7392393</ArticleId>
            <ArticleId IdType="pubmed">32730238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tenforde MW, Self WH, Naioti EA, et al.
Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults — United States, March–July 2021.
MMWR Morb Mortal Wkly Rep
2021;70:1156-1162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8389395</ArticleId>
            <ArticleId IdType="pubmed">34437524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajema KL, Dahl RM, Prill MM, et al.
Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalization — five veterans affairs medical centers, United States, February 1–August 6, 2021.
MMWR Morb Mortal Wkly Rep
2021;70:1294-1299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8445376</ArticleId>
            <ArticleId IdType="pubmed">34529636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gottlieb RL, Nirula A, Chen P, et al.
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.
JAMA
2021;325:632-644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7821080</ArticleId>
            <ArticleId IdType="pubmed">33475701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horby PW, Mafham M, Peto L, et al.
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
June
16, 2021.  (https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1). preprint.</Citation>
        </Reference>
        <Reference>
          <Citation>Pogue JM, Lauring AS, Gandhi TN, et al.
Monoclonal antibodies for early treatment of COVID-19 in a world of evolving SARS-CoV-2 mutations and variants.
Open Forum Infect Dis
2021;8(7):ofab268-ofab268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8194619</ArticleId>
            <ArticleId IdType="pubmed">34291118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cowman K, Guo Y, Pirofski LA, et al.
Post-severe acute respiratory syndrome coronavirus 2 monoclonal antibody treatment hospitalizations as a sentinel for emergence of viral variants in New York City.
Open Forum Infect Dis
2021;8(8):ofab313-ofab313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8391090</ArticleId>
            <ArticleId IdType="pubmed">34458391</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
